必威·betway(西汉姆联)官方网站-West Ham United
Welcome to Beijing Beilu Pharmaceutical Co., Ltd.
-简体中文
-繁体中文
-English
HOME
ABOUT BEILU
Company Profile
History
Industry Focus
Production Base
Hichi Pharma
Enterprise Culture
Beilu Culture
Team Building Activities
Honor
PRODUCTS
Contrast Agents
Central Nervous System Product
Oral Anti-diabetic Drugs
Sales Consult
Jiuwei Classroom
PRECISION MEDICINE
GENESEEQ
YZYMED
医未医疗
NEWS
INVESTOR RELATIONS
Articles of Association
Social Responsibility Report
Information Disclosure
Dividend
JOIN BEILU
Talent Strategy
Campus Recruitment
Social Recruitment
CONTACT US
Company Profile
History
Industry Focus
Production Base
Hichi Pharma
Enterprise Culture
Beilu Culture
Team Building Activities
Honor
Company History
2023
为积极落实中药领域的战略布局、提升产品盈利能力和市场竞争力、打造“第二增长曲线”重要举措，结合建设“第四生产基地”的规划，全资子公司陆芝葆药业有限公司取得安徽省亳州市143亩工业用地使用权。
2023
为积极落实中药领域的战略布局、提升产品盈利能力和市场竞争力、打造“第二增长曲线”重要举措，结合建设“第四生产基地”的规划，全资子公司陆芝葆药业有限公司取得安徽省亳州市143亩工业用地使用权。
2022
公司全资研发子公司艾湃克斯医药研发有限公司正式投入运营，将担负起Betway必威西汉姆联产品创新升级业务，为公司“二次创业”注入新动能。
2022
公司全资研发子公司艾湃克斯医药研发有限公司正式投入运营，将担负起Betway必威西汉姆联产品创新升级业务，为公司“二次创业”注入新动能。
2020
公司完成对浙江海昌药业股份有限公司的收购，海昌药业成为公司控股子公司。
公司完成向不特定对象发行可转换公司债券，募集资金5亿元，债券简称：Betway必威西汉姆联转债，债券代码：123082。
2020
公司完成对浙江海昌药业股份有限公司的收购，海昌药业成为公司控股子公司。
公司完成向不特定对象发行可转换公司债券，募集资金5亿元，债券简称：Betway必威西汉姆联转债，债券代码：123082。
2019
Beilu Pharm invested Shanghai Dr.Brain Medical Technology Co., Ltd, gradually realizing personalized diagnostic and treatment dual platforms coordinated development strategy target.
2019
Beilu Pharm invested Shanghai Dr.Brain Medical Technology Co., Ltd, gradually realizing personalized diagnostic and treatment dual platforms coordinated development strategy target.
2018
Beilu Pharm invested in Zhejiang Hichi Pharmaceutical Co., Ltd to improve the strategic layout of industrial chain integration.
2018
Beilu Pharm invested in Zhejiang Hichi Pharmaceutical Co., Ltd to improve the strategic layout of industrial chain integration.
2017
The company’s original research product Jiuwei Zhenxin Granules was included in the national medical insurance catalogue.
2017
The company’s original research product Jiuwei Zhenxin Granules was included in the national medical insurance catalogue.
2016
Beilu Pharm invested in Wuhan YZY Medical Science &Technology Co., Ltd, and gradually realizing the strategic layout of the precision medical field.
2016
Beilu Pharm invested in Wuhan YZY Medical Science &Technology Co., Ltd, and gradually realizing the strategic layout of the precision medical field.
2015
The company established Cangzhou branch company in Cangzhou Lingang Economic and Technological Development Zone, and built the traditional Chinese medicine extraction and raw material production base.
The company launched iodine contrast agent Iopamidol Injection as the fisrt generic in China.
2015
The company established Cangzhou branch company in Cangzhou Lingang Economic and Technological Development Zone, and built the traditional Chinese medicine extraction and raw material production base.
The company launched iodine contrast agent Iopamidol Injection as the fisrt generic in China.
2014
Beilu Pharm invested in Geneseeq Technology Inc., and gradually realizing the company's strategic layout in the field of precision medicine.
2014
Beilu Pharm invested in Geneseeq Technology Inc., and gradually realizing the company's strategic layout in the field of precision medicine.
2013
The injection workshop completed according to EU standard successfully passed the national new GMP certification.
2013
The injection workshop completed according to EU standard successfully passed the national new GMP certification.
2011
Approved by Beijing Municipal Commission of Development and Reform, the company built the Beijing Engineering Laboratory for biomedical imaging drug.
Beilu pharm first launched generic Anti-diabetic drug Repaglinide Tablets (®Ruiliean) in China.
The company launched iodine contrast agent Iodixanol Injection.
2011
Approved by Beijing Municipal Commission of Development and Reform, the company built the Beijing Engineering Laboratory for biomedical imaging drug.
Beilu pharm first launched generic Anti-diabetic drug Repaglinide Tablets (®Ruiliean) in China.
The company launched iodine contrast agent Iodixanol Injection.
2010
Beilu Pharm was selected as the first batch of large-scale enterprises in the Beijing Biomedical Industry Leap-forward Development Project (G20 Project).
2010
Beilu Pharm was selected as the first batch of large-scale enterprises in the Beijing Biomedical Industry Leap-forward Development Project (G20 Project).
2009
In the first batch of listings on Shenzhen Stock Exchange’ GEM, issued 17 million A shares, and the share capital was 67.888491 million shares after issuing. 【 stock code: 300016】
2009
In the first batch of listings on Shenzhen Stock Exchange’ GEM, issued 17 million A shares, and the share capital was 67.888491 million shares after issuing. 【 stock code: 300016】
2008
The only CFDA approved, company’s self-developed domestic anti-anxiety Chinese Patent drug Jiuwei Zhenxin Granules(®Jiuwei) was successfully launched.
2008
The only CFDA approved, company’s self-developed domestic anti-anxiety Chinese Patent drug Jiuwei Zhenxin Granules(®Jiuwei) was successfully launched.
2006
The company was officially listed in the Agency Share Transfer System of the Shenzhen Stock Exchange [stock code 430006].
2006
The company was officially listed in the Agency Share Transfer System of the Shenzhen Stock Exchange [stock code 430006].
2004
The company launched the first exclusive oral MRI contrast agent-Ferric Ammonium Citrate Effervescent Granules, which is oral used for the diagnosis of gastrointestinal tract.
2004
The company launched the first exclusive oral MRI contrast agent-Ferric Ammonium Citrate Effervescent Granules, which is oral used for the diagnosis of gastrointestinal tract.
2003
The company set up Miyun pharmaceutical factory in Miyun Industrial Development Zone to build a modern pharmaceutical production base.
2003
The company set up Miyun pharmaceutical factory in Miyun Industrial Development Zone to build a modern pharmaceutical production base.
2001
Beijing Beilu Pharmaceutical Company was legally changed to Beijing Beilu Pharmaceutical Co.,Ltd with a capital stock of 383,884.91 million shares.
The company’s first Anti-diabetes product Glimepiride Tablets (® Dibei) was first released in China.
2001
Beijing Beilu Pharmaceutical Company was legally changed to Beijing Beilu Pharmaceutical Co.,Ltd with a capital stock of 383,884.91 million shares.
The company’s first Anti-diabetes product Glimepiride Tablets (® Dibei) was first released in China.
1999
The company was restructured as Beijing Beilu Pharmaceutical Company with the registered capital of RMB 35,250,000.
1999
The company was restructured as Beijing Beilu Pharmaceutical Company with the registered capital of RMB 35,250,000.
1998
The company launched the first iodine contrast agent Iohexol Injection.
1998
The company launched the first iodine contrast agent Iohexol Injection.
1996
Beijing Beilu Pharmaceutical Chemical Co., Ltd was restructured as a joint-stock cooperative enterprise, and renamed as Beijing Beilu Pharmaceutical Chemical Group.
1996
Beijing Beilu Pharmaceutical Chemical Co., Ltd was restructured as a joint-stock cooperative enterprise, and renamed as Beijing Beilu Pharmaceutical Chemical Group.
1992
Beijing Beilu Pharmaceutical Chemical Co., Ltd was established, and launched the first domestic MRI contrast agent Gadopentetate Dimeglumine Injection, which broke the foreign pro-duct’s monopoly and filled a domestic gap in China.
1992
Beijing Beilu Pharmaceutical Chemical Co., Ltd was established, and launched the first domestic MRI contrast agent Gadopentetate Dimeglumine Injection, which broke the foreign pro-duct’s monopoly and filled a domestic gap in China.
2011
